ArticleAdvanced healthcare materials2026
A Lightweight, 3D-Printable, Low-Cost, "One-Click" Dorsal Skin Window for High-Quality Long-Term Multimodal Subcutaneous Tumor Imaging.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Intravital microscopy (IVM) using dorsal skinfold chambers (DSCs) enables real-time, high-resolution imaging of the tumor microenvironment. Conventional, metal-based DSC systems often cause animal distress and require technically demanding surgical implantation. To address these challenges and adhere to the 3Rs principles of animal welfare, this study presents a novel, stereolithography (SLA)-based, 3D-printed DSC featuring a lightweight (0.69 g) biocompatible resin structure and a suture-free "one-click" fixation system. This affordable device simplifies surgical installation and minimizes postoperative inflammation, allowing continuous multimodal imaging-IVM, micro-CT, ultrasound, and in vivo fluorescence-for up to four weeks. The system is validated in mice bearing subcutaneous tumors generated from PDAC93-GFP pancreatic tumor organoids implanted in the DSC. Longitudinal, high-resolution imaging successfully tracks tumor expansion, active stromal remodeling characterized by progressive collagen fiber compaction and alignment, and the emergence of a highly tortuous peritumoral vascular network. Furthermore, in vivo tracking in Catchup mice reveals a distinct transition of tumor-associated neutrophils from random acute inflammatory migration to directed tumor-driven chemotaxis. Overall, this ergonomic and robust DSC design provides a highly reliable platform for sustained, high-quality assessment of tumor-stroma-immune interactions and therapeutic responses, while notably improving animal welfare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.